Humanwell Healthcare (600079.SH): HW241045 tablets approved for clinical trials of drugs.
People's Pharmaceutical Group (600079.SH) announced that its wholly-owned subsidiary, Wuhan People's Pharmaceuticals Innovation Drug Research Center Co., Ltd...
Healthcare company Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary, Wuhan Humanwell Innovation Drug Research Center Co., Ltd., has recently received approval from the National Medical Products Administration for HW241045 tablets to conduct clinical trials. HW241045 tablets are used for the treatment of idiopathic pulmonary fibrosis, and currently there are no drugs with the same target approved for marketing globally.
Related Articles
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Northeast: Music ecosystem giant NETEASE MUSIC (09899) benefits from rapid industry growth.
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
